← Back to headlines
Truist Lowers Price Target for Neurocrine Biosciences (NBIX) After 2026 Outlook
Truist has reduced its price target for Neurocrine Biosciences, Inc. (NBIX) following the company's update on its 2026 financial outlook.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
